GlassScriptPhysician profile
Leslie Jones
NPI 1023129566
$3,054.46
in general payments reported to CMS, 2019-2025
20 companies · $570 in 2025
The $570 reported for 2025 was more than what 81% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $571 · 2020: $393 · 2021: $487 · 2022: $401 · 2023: $363 · 2024: $269 · 2025: $570.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,202.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,202.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tris Pharma INC | $731.65 | 2019-2024 | Dyanavel Xr |
| Biosense Webster, INC. | $388.31 | 2025 | Carto 3 |
| Takeda Pharmaceuticals U.S.A., INC. | $324.05 | 2019-2022 | |
| Sanofi Pasteur INC. | $290.93 | 2019-2025 | |
| Ironshore Pharmaceuticals INC. | $283.88 | 2019-2024 | Jornay Pm |
| Glaxosmithkline, LLC. | $224.85 | 2019-2025 | Bexsero, Pediarix |
| Pfizer INC. | $172.67 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $154.80 | 2020-2025 | Vaxneuvance, Gardasil 9, Vaqta |
| Corium, LLC | $154.74 | 2022-2025 | Azstarys |
| Supernus Pharmaceuticals, INC. | $72.45 | 2021-2023 | Qelbree |
| Arbor Pharmaceuticals, INC. | $50.01 | 2019 | |
| Seqirus USA INC | $46.24 | 2024-2025 | Flucelvax |
| Neos Therapeutics, LP | $40.37 | 2019-2020 | |
| Collegium Pharmaceutical, INC. | $37.07 | 2025 | Jornay Pm |
| Genentech USA, INC. | $18.11 | 2019 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sobi, INC | $14.97 | 2019 | |
| Adlon Therapeutics L.P. | $13.91 | 2021 | |
| Novartis Pharmaceuticals Corporation | $12.22 | 2019 | |
| Mission Pharmacal Company | $12.10 | 2019 | |
| Almirall LLC | $11.13 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Leslie Jones listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.